Rafael Holdings, Inc.

NYSE RFL

Rafael Holdings, Inc. Market Capitalization on February 07, 2025: USD 49.24 M

Rafael Holdings, Inc. Market Capitalization is USD 49.24 M on February 07, 2025, a -10.53% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.

Rafael Holdings, Inc. 52-week high Market Capitalization is USD 70.53 M on October 11, 2024, which is 43.23% above the current Market Capitalization.
Rafael Holdings, Inc. 52-week low Market Capitalization is USD 40.47 M on August 16, 2024, which is -17.81% below the current Market Capitalization.
Rafael Holdings, Inc. average Market Capitalization for the last 52 weeks is USD 50.63 M.

Key data

Date	Market Capitalization	Share Price	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)

NYSE: RFL

Rafael Holdings, Inc.

CEO	Mr. William Conkling
IPO Date	March 27, 2018
Location	United States
Headquarters	520 Broad Street
Employees	13
Sector	Real Estate
Industries Health Care REITs Office REITs

Description

Rafael Holdings, Inc. holds interests in clinical and early stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. The company operates in two segments, Pharmaceuticals and Real Estate. It engages in the leasing of a commercial office building, as well as an associated 800-car public garage; and development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The company's lead drug candidate is CPI-613 (devimistat), which is being evaluated in various clinical studies, including two Phase III registrational clinical trials for the treatment of metastatic pancreatic cancer and r/r acute myeloid leukemia. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.

Key trends

Past 5 years